SPHK1 and neoplasm: In conclusion, our current observations demonstrate that targeting SK1 is a promising option as inhibition of this specific lipid kinase affects (i) the primary tumor growth, (ii) the intratumoral CD8/Treg ratio (iii) the immunotherapy efficacy by immune checkpoint blockade such as anti-CTLA-4 or anti-PD-1.